Tech Company Financing Transactions
BEAT BioTherapeutics Funding Round
On 4/17/2013, BEAT BioTherapeutics received $2.5 million in Seed funding from CET Capital Partners and W Fund.
Transaction Overview
Company Name
Announced On
4/17/2013
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Seed
Investors
CET Capital Partners (Craig Tall)
Proceeds Purpose
The proceeds will be used to move BEATBio's lead gene therapy product into clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1380 112th Ave. Southeast 200
Seattle, WA 98004
USA
Seattle, WA 98004
USA
Phone
Website
Email Address
Overview
BEAT BioTherapeutics develops novel therapies for heart diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Kranda
Chief Medical Officer
Sam Teichman
Browse more venture capital transactions:
Prev: 4/17/2013: XLerant venture capital transaction
Next: 4/17/2013: BlueCava venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs